Business Context and Reporting Period
Eledon Pharmaceuticals, Inc. (ELDN) filed a Form 8-K on August 11, 2025, regarding events occurring in August 2025. The filing addresses the Company's financial results for the quarter ended June 30, 2025, and announces a material restatement of previously issued financial statements due to accounting errors.
Key Financial Metrics
The filing references a press release issued on August 14, 2025, containing results for the quarter ended June 30, 2025, but does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity within this text. The filing explicitly states that the identified accounting errors did not impact the Company's cash and short-term investment position, liquidity, or results of operations.
Material Changes and Restatement
The Company identified a material misstatement in its accounting for Series X and Series X-1 non-voting convertible preferred stock. Previously classified as permanent equity, the stock is being reclassified as temporary equity because its rights are substantially identical to common stock and it contains a provision for potential cash settlement upon a fundamental transaction. Consequently, the following reports are materially misstated and should no longer be relied upon:
- 2024 Form 10-K (fiscal years ended Dec 31, 2024 and 2023).
- 2025 Form 10-Q (quarter ended March 31, 2025).
- 2024 Quarterly Reports (quarters ended March 31, June 30, and September 30, 2024).
The Company will amend the 2024 Form 10-K and 2025 Form 10-Q to restate the financial statements. The 2024 quarterly reports will not be amended individually; instead, the restatement effects will be summarized in the amended 2024 Form 10-K and reflected prospectively in 2025 quarterly filings.
Guidance, Risks, and Internal Controls
The Company identified a material weakness in its internal control over financial reporting related to the accounting for equity instruments. As a result, management concluded that internal controls were not effective as of December 31, 2024, and disclosure controls were not effective as of March 31, 2024, June 30, 2024, September 30, 2024, December 31, 2024, and March 31, 2025. The Company has discussed these matters with its independent auditors, Deloitte & Touche LLP, and its predecessor firms.
Investor Verification Checklist
- Verify the specific financial figures for the quarter ended June 30, 2025, in the attached press release (Exhibit 99.1) as they are not detailed in the 8-K text.
- Monitor upcoming amendments to the 2024 Form 10-K and 2025 Form 10-Q for the restated balance sheets and earnings per share calculations.
- Review the Company's remediation plan for the material weakness in internal controls over financial reporting.
- Confirm the reclassification of Series X and Series X-1 preferred stock from permanent to temporary equity in future filings.